Doxorubicin Loaded Nano-Gel Preoperative Application Effect as Adjuvant Chemotherapy on Osteosarcoma

Abstract

This paper aimed to observe the effect of adjuvant chemotherapy with adriamycin loaded nano-gel on osteosarcoma. 120 patients with osteosarcoma who visited the hospital from January 2018 to February 2022 were selected as control group and nano group by the red blue ball method. The control group received conventional doxorubicin combined with ifosfamide chemotherapy. The nano group was treated with doxorubicin loaded nano-gel as adjuvant chemotherapy before surgery. Both groups received limb salvage surgery. Serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) were compared between two groups before, after, and 1 day after chemotherapy. Follow up records were kept for 12 months to obtain adverse reactions to chemotherapy, postoperative clinical efficacy, and progression free survival time (PFS). No significant difference existed in ALP, LDH, VEGF, and bFGF levels between two groups of patients before chemotherapy (P > 0.05). For the overall comparison, inter group, time, and interaction effects had statistical significance (P < 0.05). For the comparison of two groups, the average ALP, LDH, VEGF, and bFGF in the nano group were lower after chemotherapy. The incidence of grade III–IV adverse reactions in the nano group was 10% lower than the controlling group. The CR+PR rate in the nano group was higher. The preoperative application of adriamycin loaded nano-gel as adjuvant chemotherapy can make the patients’ prognosis with osteosarcoma improved. It can enhance the chemotherapy effect, control the degree of adverse reactions of chemotherapy, and improve the clinical efficiency, thus extending the progression free survival period of patients with osteosarcoma.